What's Happening?
Roche has announced promising results from a phase 3 trial of its experimental KRAS G12C inhibitor, divarasib, in patients with non-small cell lung cancer (NSCLC). The trial, Krascendo 1, compared divarasib to Amgen's Lumakras and Bristol Myers Squibb's
Krazati, showing that divarasib was more effective in delaying disease progression and extending survival. The study demonstrated a statistically significant improvement in progression-free survival and overall survival, suggesting divarasib's potential as a best-in-class treatment. Roche plans to use these results for regulatory filings. The company is also conducting additional trials to explore divarasib's use in combination with other treatments and in earlier stages of the disease.
Why It's Important?
The success of divarasib in this trial is a significant development in the treatment of KRAS G12C-mutated NSCLC, a challenging cancer subtype. This could lead to a new standard of care for patients who have limited treatment options. The results also highlight the potential for divarasib to capture market share from existing KRAS inhibitors, which have faced commercial challenges despite their scientific breakthroughs. For patients, this could mean improved outcomes and more treatment choices. For Roche, this success could enhance its position in the oncology market and drive future growth.
